8-K
filed April 22, 2026, 7:59 PM ET
ticker CCI
CIK 0001051470
earnings
confidence low
sentiment neutral
materiality 0.50
Crown Castle maintains FY2026 outlook; site rental revenues seen falling 5% to $3.85B
CROWN CASTLE INC.
2026-Q1 EPS reported
$0.34
revenue$1,010,000,000
- Maintains FY2026 outlook: site rental revenues midpoint $3,850M, down 5% vs FY2025 $4,049M.
- Net income outlook midpoint $780M, up 76% from FY2025 $444M.
- Adjusted EBITDA outlook midpoint $2,690M, down 6% from FY2025 $2,863M.
- AFFO per share outlook midpoint $4.43, up 2% from FY2025 $4.36.
- Outlook unchanged from previous guidance issued February 4, 2026.
Machine-readable event card
- schema_version
- secwatch.filing_event.v1
- accession
- 0001051470-26-000046
- form_type
- 8-K
- ticker
- CCI
- cik
- 0001051470
- company_name
- CROWN CASTLE INC.
- filed_at
- 2026-04-22T23:59:59+00:00
- discovered_at
- 2026-05-14T18:02:31.873664+00:00
- generated_at
- 2026-05-15T04:49:09.925957+00:00
- sec_items
- ["2.02", "7.01", "9.01"]
- event_type
- earnings
- sentiment
- neutral
- materiality_score
- 0.5
- calibrated_materiality_score
- 0.5
- confidence
- low
- secwatch_canonical_url
- https://secwatch.observer/filing/0001051470-26-000046
- json_url
- https://secwatch.observer/filing/0001051470-26-000046.json
- markdown_url
- https://secwatch.observer/filing/0001051470-26-000046.md
- text_url
- https://secwatch.observer/filing/0001051470-26-000046.txt
- edgar_index_url
- https://www.sec.gov/Archives/edgar/data/1051470/000105147026000046/0001051470-26-000046-index.htm
- edgar_primary_document_url
- https://www.sec.gov/Archives/edgar/data/1051470/000105147026000046/cci-20260422.htm
- generated_by_model
- deepseek-v4-flash:cloud@v2
- review_status
- machine_generated
- human_reviewed
- false
- corrected
- false
- correction_note
- null
- correction_timestamp
- null
- superseded_by
- null
Comparable filings
EXPI
eXp World Holdings Q1 revenue $1.0B (+5% YoY), net loss narrows to $(5.1M), Adj. EBITDA $4.1M (+88%)
eXp World Holdings, Inc.
May 11, 2026, 7:59 PM ET
earnings
Items 2.02, 7.01, 9.01
same fact type: earnings_release
same SEC item: 2.02, 7.01, 9.01
same event type: earnings
similar materiality
This filing
Crown Castle Inc. (NYSE: CCI) ("Crown Castle") today reported results for the first quarter ended March 31, 2026, and maintained its full year 2026 Outlook, as reflected in the table below.
Comparable filing
the company's scale and our focus on operational efficiency across eXp World Holdings,” said Jesse Hill, Chief Financial Officer of eXp World Holdings. “We generated revenue of $1.0 billion and Adjusted EBITDA of $4.1 million, an 88% improvement that further strengthened our financial position. More recently, we executed the strategic NextHome acquisition using cash
Filing page
SEC filing
CGBD
Carlyle Secured Lending Q1 NII $0.36/sh; NAV down 2.3% to $15.89; declares $0.35 dividend
Carlyle Secured Lending, Inc.
May 11, 2026, 7:59 PM ET
earnings
Items 2.02, 7.01, 9.01
same fact type: earnings_release
same SEC item: 2.02, 7.01, 9.01
same event type: earnings
similar materiality
This filing
Crown Castle Inc. (NYSE: CCI) ("Crown Castle") today reported results for the first quarter ended March 31, 2026, and maintained its full year 2026 Outlook, as reflected in the table below.
Comparable filing
For the first quarter of 2026, we reported $0.36 per common share of Net Investment Income and Adjusted Net Investment Income, a non-GAAP financial measure described below.
Filing page
SEC filing
ENTXW
Entera Bio Q1 net loss $3.5M; cash $20.4M; EB613 Phase 3 protocol submitted to FDA
Entera Bio Ltd.
May 8, 2026, 7:59 PM ET
earnings
Items 2.02, 7.01, 9.01
same fact type: earnings_release
same SEC item: 2.02, 7.01, 9.01
same event type: earnings
similar materiality
This filing
Crown Castle Inc. (NYSE: CCI) ("Crown Castle") today reported results for the first quarter ended March 31, 2026, and maintained its full year 2026 Outlook, as reflected in the table below.
Comparable filing
Entera Bio Ltd. (NASDAQ: ENTX) ("Entera" or the "Company"), a leader in the development of oral peptides, today reported financial results and key business updates for the quarter ended March 31, 2026.
Filing page
SEC filing
RPC
Ridgepost Capital reports record AUM of $31B in Q1 2026, up 18% YoY
Ridgepost Capital, Inc.
May 8, 2026, 7:59 PM ET
earnings
Items 2.02, 7.01, 8.01, 9.01
same fact type: earnings_release
same SEC item: 2.02, 7.01, 9.01
same event type: earnings
similar materiality
This filing
Crown Castle Inc. (NYSE: CCI) ("Crown Castle") today reported results for the first quarter ended March 31, 2026, and maintained its full year 2026 Outlook, as reflected in the table below.
Comparable filing
Ridgepost Capital, Inc (NYSE: RPC), a leading private markets solutions provider, today announced financial results for the first quarter ended March 31, 2026.
Filing page
SEC filing
HAIN
Hain Celestial reports Q3 FY2026 earnings; detailed figures not included in filing excerpt
HAIN CELESTIAL GROUP INC
May 11, 2026, 7:59 PM ET
earnings
Items 2.02, 9.01
same fact type: earnings_release
same SEC item: 2.02, 9.01
same event type: earnings
similar materiality
This filing
Crown Castle Inc. (NYSE: CCI) ("Crown Castle") today reported results for the first quarter ended March 31, 2026, and maintained its full year 2026 Outlook, as reflected in the table below.
Comparable filing
On May 11, 2026, The Hain Celestial Group, Inc. (the “Company”) issued a press release announcing financial results for its third quarter ended March 31, 2026.
Filing page
SEC filing
HRTX
Heron Q1 net revenue $34.7M (-10.8% YoY); Acute Care up 32%; guidance reaffirmed
HERON THERAPEUTICS, INC. /DE/
May 11, 2026, 7:59 PM ET
earnings
Items 2.02, 9.01
same fact type: earnings_release
same SEC item: 2.02, 9.01
same event type: earnings
similar materiality
This filing
Crown Castle Inc. (NYSE: CCI) ("Crown Castle") today reported results for the first quarter ended March 31, 2026, and maintained its full year 2026 Outlook, as reflected in the table below.
Comparable filing
Reaffirms Guidance - Q1 2026 net revenue growth year-over year for Acute Care franchise (+32%), including ZYNRELEF ® (+27%) and APONVIE ® (+50%) - Q1 2026 total net revenue of $34.7 million - Reached settlement with Baxter Healthcare Corporation in CINVANTI ® patent litigation - Reaffirmed 2026 full-year guidance of $173–$183 million net revenue; $10–$20 million
Filing page
SEC filing
XGN
Exagen Q1 2026: Record revenue $17.3M, net loss $4.0M; FY guidance reaffirmed
EXAGEN INC.
May 11, 2026, 7:59 PM ET
earnings
Items 2.02, 9.01
same fact type: earnings_release
same SEC item: 2.02, 9.01
same event type: earnings
similar materiality
This filing
Crown Castle Inc. (NYSE: CCI) ("Crown Castle") today reported results for the first quarter ended March 31, 2026, and maintained its full year 2026 Outlook, as reflected in the table below.
Comparable filing
Trailing-twelve-month average selling price (ASP) $ 444 $ 419 Cash and cash equivalents $ 21,513 $ 11,194 First Quarter 2026 Highlights: • Achieved record total revenue of $17.3 million, an increase of 12% compared to first quarter 2025. • Grew AVISE CTD test volume 10% compared to first quarter 2025. • Expanded AVISE CTD trailing-twelve-month ASP to $444 per
Filing page
SEC filing
OPAL
OPAL Fuels Q1 2026 Adj EBITDA $16.7M, net loss $(5.6)M; revenue down 14% YoY
OPAL Fuels Inc.
May 11, 2026, 7:59 PM ET
earnings
Items 2.02, 9.01
same fact type: earnings_release
same SEC item: 2.02, 9.01
same event type: earnings
similar materiality
This filing
Crown Castle Inc. (NYSE: CCI) ("Crown Castle") today reported results for the first quarter ended March 31, 2026, and maintained its full year 2026 Outlook, as reflected in the table below.
Comparable filing
Revenue for the three months ended March 31, 2026 and 2025, was $73.4 million and $85.4 million respectively, a decrease of (14)%, compared to the same period last year. 1 • Net (loss) income for the three months ended March 31, 2026 was $(5.6) million, compared to $1.3 million in the same period last year. • Basic and diluted net loss per share attributable to Class A common shareholders for the three months ended months ended March 31, 2026 were $(0.09) compared to $(0.01) in the comparable period last year.
Filing page
SEC filing
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.